Comparative Pharmacology
Head-to-head clinical analysis: GLYCOPYRROLATE versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCOPYRROLATE versus HICON.
GLYCOPYRROLATE vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycopyrrolate is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors in the autonomic nervous system, thereby reducing salivary, gastric, and bronchial secretions. It also exhibits antispasmodic effects on gastrointestinal smooth muscle.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
1-2 mg orally 2-3 times daily; maximum 8 mg/day. For parenteral use: 0.1-0.2 mg IV/IM every 4-6 hours as needed.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal elimination half-life: 0.6-1.2 hours (IM/IV), with prolonged duration in elderly and renal impairment.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Primarily renal excretion of unchanged drug (85-90%) with biliary/fecal elimination accounting for <10%.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic